The approach to HoFH children has to be slightly different from the one to HeFH paediatric patients despite the fact that HeFH children might have LDL-C in the range typical for HoFH, that is, !5-10 mmol/l ($400-500 mg/dl). 2 For HoFH children the treatment based only upon healthy lifestyle (diet, regular exercise, etc.) and statin therapy is virtually never enough. It has to be stressed that doses, especially in very small children, are totally arbitrary because, for obvious reasons, no trials, particularly no randomized placebocontrolled trials, in these children have been performed. The first trial on HoFH children (the mean age was 10.9 years) with a statin which was published most recently demonstrated that rosuvastatin 20 mg/day alone or added to ezetimibe and/or apheresis is safe and that such a treatment can reduce LDL-C effectively.
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A recent meta-analysis of all trials with statin treatment of children aged 6-17 years with HeFH have demonstrated significant reductions and statins seem to be safe and well-tolerated in these patients. 10 Nevertheless, even adding ezetemibe to the maximally tolerable statin doses is often not enough to decrease extremely elevated LDL-C to the required levels. Still, there are not many data on HoFH children younger than 6-8 years. It is very important since children with familial hypercholesterolaemia (both HeFH and HoFH) have greater mean carotid intima-media thickness (cIMT) values as compared with their unaffected siblings even at the age of 6-8 years and it is generally accepted that the measurement of cIMT and/or screening for atherosclerotic plaques by carotid artery ultrasound can add information beyond assessment of traditional risk factors, including elevated LDL-C, in asymptomatic adults at moderate CVD risk. 11, 12 It has also been shown that exposure to high LDL-C in childhood and adolescence predicts increased cIMT and decreased elasticity in young adulthood. 13, 14 It is quite clear that the treatment of paediatric HoFH patients has to start as early as possible, that is, immediately at the initial diagnosis, as they have an extremely high risk of premature CVD and death in childhood or the teenage period.
14 The LDL-C goals in these children are also not based upon any trials. For instance, the European consensus on familial hypercholesterolaemia recommends LDL-C <3.5 mmol/l ($135 mg/dl) as a target for paediatric patients regardless of whether they have HoFH or HeFH and regardless of their age.
1 This is certainly not enough when children with HoFH are in question. The reason for such conservatively high levels of LDL-C, owing to lack of data, was the concern regarding statin treatment in very young children (<8 or even <10 years) that inhibiting endogenous synthesis might have serious multiorgan consequences. Namely, it is known that cholesterol has many essential functions in normal cell physiology, of particular importance in the central nervous system, as precursor of steroid hormones and bile acids, especially during the developmental period of early childhood. 15 Today, no such concerns still exist since there are no published reports indicating that statin treatment in children with either HeFH or, particularly, HoFH can cause harm due to inhibition of endogenous cholesterol synthesis, but, on the contrary, that they will benefit from such treatment.
Often statin treatment, even when combined with ezetimibe, is not enough to decrease sufficiently LDL-C in HoFH children. Therefore, this treatment can be combined with lipoprotein apheresis, which is feasible even in very young children. In this issue of EJPC is an article describing the results of lipoprotein apheresis among six children with HoFH; the youngest patient who started the LDL apheresis treatment was two years and five months old, being the youngest child treated so far with this method. 16 Before this, the youngest child treated by LDL apheresis was 3.5 years old 17 and also, one of our patients with HoFH who was the youngest patient at that time who started the treatment with statins (only three years old) 18 was also the youngest patient treated by a combination of a statin and ezetimibe as well as with LDL apheresis above statin therapy.
14 This boy is today, 15 years later, without any xanthomas, which he had in large quantities, and he has not had any cardiovascular event so far. Anyhow, as stressed by Buonuomo et al., 16 lipoprotein apheresis should be started as early as possible when treatment with medicines is insufficient. Of course, one of the problems with apheresis might be the frequency because there are reports from some countries indicating that not only is diagnosis of HoFH often delayed, and LDL-C targets not reached, but that lipoprotein apheresis frequencies are not optimal. 19 So, for example, in a recent Turkish study analysing not only children but adults as well, only 12.5% patients were undergoing apheresis weekly and the mean frequency of apheresis sessions was 19 AE 13 days, which is clearly not enough for HoFH patients. The other problem with lipoprotein apheresis is that it has limited availability, it is expensive and it is invasive and time-consuming.
Are there any other drugs except statins and ezetimibe that could be used in the treatment of HoFH paediatric patients? The results of treatment of seven HoFH patients aged 12-18 years who received mipomersen (an antisense oligonucleotide that inhibits the synthesis of apolipoprotein B100 -the main apolipoprotein of LDL particles) during 52 or 104 weeks achieved mean LDL-C reductions from a baseline of 42.7%. 20 However, it is well known from studies on adult patients that this drug has many adverse effects such as injection site reactions (78%) and flu-like symptoms (34%), but also some which are much more serious such as elevations in transaminases and liver fat content. 21 Liver transplantation is also one of the possibilities of treatment for children with HoFH but this aggressive method should be applied only for those paediatric patients with proven CVD and persistently elevated serum LDL-C despite maximum medical therapy. However, it has to be mentioned that in these children aortic valvular disease may progress. 22 Because of high operative risk and problems of lifelong immunosuppression, liver transplantation should remain as a last resort for paediatric patients with HoFH.
Recently a new group of drugs -inhibitors of PCSK-9 -has emerged as a most promising approach for treating severe hypercholesterolaemia, including HoFH, being able to reduce LDL-C by up to 65% while at the same time being well tolerated. [23] [24] [25] Still, despite many published studies with these drugs, there are very few data concerning their effects on paediatric patients with HoFH. The TESLA Part B trial with evolucomab included patients with HoFH from the age of 12 but not those younger than this. 26 It has to be stressed that although PCSK-9 inhibitors can reduce LDL-C dramatically, in those with null genes for the LDL receptor they are most probably ineffective. 27 The results of trials with PCSK9 inhibitors in HoFH paediatric patients are therefore eagerly awaited.
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